Contrast-induced nephropathy following angiography and cardiac interventions by Rear, R et al.
INVASIVE IMAGING, CARDIAC CATHETERISATION AND ANGIOGRAPHY
Contrast-induced nephropathy following
angiography and cardiac interventions
Roger Rear,1 Robert M Bell,1 Derek J Hausenloy1,2,3,4
1The Hatter Cardiovascular
Institute, University College
London, London, UK
2The National Institute of
Health Research University
College London Hospitals
Biomedical Research Centre,
London, UK
3National Heart Research
Institute Singapore, National
Heart Centre Singapore,
Singapore, Singapore
4Cardiovascular and Metabolic
Disorders Program, Duke-
National University of
Singapore, Singapore,
Singapore
Correspondence to
Professor Derek Hausenloy,
The Hatter Cardiovascular
Institute, Institute of
Cardiovascular Science, NIHR
University College London
Hospitals Biomedical Research
Centre, University College
London Hospital & Medical
School, 67 Chenies Mews,
London WC1E 6HX, UK;
d.hausenloy@ucl.ac.uk
Received 18 March 2015
Revised 8 November 2015
Accepted 29 December 2015
To cite: Rear R, Bell RM,
Hausenloy DJ. Heart
Published Online First:
[please include Day Month
Year] doi:10.1136/heartjnl-
2014-306962
INTRODUCTION
Contrast-induced nephropathy (CIN), also known
as contrast-induced acute kidney injury, is an iatro-
genic renal injury that follows intravascular admin-
istration of radio-opaque contrast media (CM) in
susceptible individuals. CIN was ﬁrst described
during the 1950s in case reports of fatal acute renal
failure that had occurred following intravenous
pyelography in patients with renal disease arising
from multiple myeloma.1 2 Despite technological
advances, CIN remains responsible for a third of all
hospital-acquired acute kidney injury (AKI)3 4 and
affects between 1% and 2% of the general popula-
tion and up to 50% of high-risk subgroups follow-
ing coronary angiography (CA) or percutaneous
coronary intervention (PCI).5
The proliferation of imaging methods and inter-
ventional procedures involving administration of
intravascular CM in both non-cardiac modalities
(eg, vascular CT angiography and interventional
vascular angiography) and in established (eg, CA
and PCI) and emerging cardiac modalities (eg, CT
coronary angiography (CTCA) and transcatheter
aortic valve implantation (TAVI)) has signiﬁcantly
increased the number of patients exposed to CM
and thus the number at risk of CIN. The wide-
spread adoption of primary PCI for the treatment
of acute myocardial infarction (AMI), despite sig-
niﬁcantly improving cardiovascular outcomes, has
increased the incidence of CIN due to the inherent
difﬁculties in rapidly assessing CIN risk, instigating
prophylactic measures, attendant haemodynamic
compromise and higher contrast volumes, all
known risk factors for the development of CIN.6
Despite several therapeutic approaches, the rising
age and incidence of comorbidity within the broad
cohort of cardiac patients receiving CM has
ensured that the prevention of CIN remains a sig-
niﬁcant clinical challenge.7
As will be discussed in the following sections, the
estimated risk of an individual developing CIN can
be calculated using known pre-existent clinical and
periprocedural factors, which are consistent with
the proposed pathological mechanisms of CIN.
Pre-existent stage III chronic kidney disease (CKD),
deﬁned as an estimated glomerular ﬁltration rate
(eGFR)<60 mL/min/1.73 m2 for greater than
3 months, is the most commonly identiﬁed risk
factor for CIN; however, CIN can occur in the
absence of underlying CKD if a number of other
risk factors are also present.5 Risk scoring systems
have been developed from cohort studies8 9 that
have enabled clinicians to predict the likelihood of
CIN occurrence and have allowed targeted use of
preventative therapies. The wholly iatrogenic and
predictable nature of CIN makes it a particularly
well-suited area for ongoing cardiovascular and
nephrology research, with focus on pathophysio-
logical mechanisms as well as novel risk assessment,
preventative, diagnostic and therapeutic measures.
DEFINITION AND DIAGNOSTIC CRITERIA OF
CIN
The generally accepted deﬁnition of CIN is a 25%
relative increase, or a 0.5 mg/dL (44 mmol/L) abso-
lute increase, in serum creatinine (SCr) within 72 h
of contrast exposure, in the absence of an alterna-
tive explanation.10 Criticisms of this deﬁnition
include the lack of sensitivity to minor increases in
SCr that have been shown to correlate with adverse
events,11 12 the combination of both relative and
absolute SCr changes and the absence of any func-
tional assessment such as changes in urine output,
as used in the RIFLE,13 AKIN14 and KDIGO15
classiﬁcation systems. However, this deﬁnition has
European Society of Cardiology (ESC)
curriculum section and guidelines
referenced
▸ 2.4 Invasive imaging: cardiac catheterisation
and angiography.
▸ ESC: updated contrast-induced nephropathy
(CIN) prevention guidelines 2014.
▸ European Society of Urogenital Radiology:
updated contrast media safety committee
guidelines 2011.
Learning objectives
▸ Deﬁne CIN and recognise this as a common
and serious complication in susceptible patients
receiving intravascular contrast media.
▸ Understand the possible pathological
mechanisms underlying CIN.
▸ Describe the clinical and periprocedural risk
factors for CIN and perform a risk assessment
for patients receiving contrast media.
▸ Appreciate the established strategies used to
prevent CIN and be aware of novel therapies.
▸ Recognise the onset of CIN and manage this
complication appropriately.
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the advantage of being widely used as the end
point in most CIN studies and it correlates well
with adverse clinical end points.
An alternative deﬁnition proposed by Harjai
et al16 aims to classify CIN according to three
grades corresponding to three relative and absolute
creatinine rise cut-offs, including a group with only
minor rise (<25% or 0.5 mg/dL), which also corre-
lates with long-term adverse outcomes (table 1).
A signiﬁcant problem with SCr is that it is rela-
tively insensitive to the rapid GFR changes seen in
AKI, particularly in patients with normal baseline
renal function.17 Elevations in SCr typically take
2–3 days to reach the current diagnostic threshold
following an acute renal insult, thus reducing its
usefulness as a marker of AKI. However early and
minor incremental changes in SCr may be a useful
marker of CIN; a recent clinical trial performed by
Ribichini et al,18 which included 216 at-risk
patients undergoing CA, demonstrated that at 12 h
a 5% increase in SCr from baseline was a sensitive
(75%) and speciﬁc (72%) marker of CIN at 48 h
and persistent worsening of renal function at
30 days.
Several novel renal biomarkers, including
NGAL,19 Cystatin C,20 urinary Kim-121 and
interleukin-1822 have been proposed to speciﬁcally
detect CIN within minutes to hours of the renal
insult. Unfortunately, to date, these biomarkers
have yet to progress beyond the realms of clinical
research; there is a clear clinical need for large trial
validation of their use in the early detection and
intervention in AKI.
ADVERSE OUTCOMES FOLLOWING CIN
CIN is often regarded in clinical practice as a
transient event; in up to 80% of cases, SCr levels
normalise after approximately 1–3 weeks.23
However, CIN is of clinical importance as a
number of clinical trials have revealed that it por-
tends a multitude of short-term and long-term
adverse events.24 After adjusting for comorbidities,
observational studies have demonstrated that
in-hospital mortality is approximately ﬁve times
higher in patients who suffer CIN compared with
patients receiving CM who do not,25 and mortality
rates at 1 and 5 years are approximately four times
higher,26 with some demonstrating a 1-year mortal-
ity rates of between 20%12 and 38%.27 In other
observational studies, as many as 20% of those
developing CIN suffer persistent worsening renal
function after CM exposure,28 with renal replace-
ment therapy occurring in between 0.7%25 and
7%27 of patients with CIN (table 2). As such the
additional healthcare costs associated with CIN are
thought to be considerable.12
However, it is important to recognise that a
direct causal relationship between CIN and mortal-
ity has not been established in these observational
studies. The onset of CIN is more likely to occur in
the presence of severe cardiac injury or disease,
which alone conveys a poor prognosis. As such
CIN may be a marker of adverse cardiovascular
outcomes rather than an independent risk factor.
A recent meta-analysis by James et al,29 reviewed
39 observational studies that investigated cardiovas-
cular outcomes in those with CIN and demon-
strated an increased risk of mortality, cardiovascular
events, renal failure and prolonged hospitalisation.
However, it was found that baseline clinical
characteristics that simultaneously predispose to
both CIN and mortality were strong confounders,
especially so in unadjusted studies. Even with
appropriate adjustment for comorbidity, the
authors recommend that any ﬁrm conclusions
about causality should be interpreted with caution.
Nonetheless, a number of plausible pathological
mechanisms exist that might explain a direct link
between CIN and major adverse cardiac events
(MACE). In the short term these include acute
volume overload, electrolyte disturbance, uraemia
or haemodialysis (HD) in cases of severe CIN.
Longer term MACE in those who suffer persistent
renal injuries may be increased secondary to the
cardiovascular risk associated with progressive
CKD and its many pathological manifestations,
including accelerated atherosclerosis, vascular calci-
ﬁcation and left ventricular (LV) hypertrophy.30
However, it is less conceivable how minor or transi-
ent changes in kidney function might increase
MACE risk.
In order to demonstrate a deﬁnite causal link
between CIN and MACE, large randomised con-
trolled trials (RCTs) are needed to demonstrate that
effective CIN prevention strategies are also able to
reduce short-term and long-term MACE, speciﬁc-
ally using therapies that offer no additional cardio-
vascular risk reduction beneﬁts. Given the
similarities that exist between renal and cardiovas-
cular disease and their respective treatments, this is
unlikely to be feasible. In view of the many
Table 1 CIN severity grading system (adapted from Harjai el al16)
CIN grade Change in serum creatinine 6 month outcomes
Grade 0 SCr increase <25% and <0.5 mg/dL above baseline MACE 12.4%
Mortality 10.2%
Grade 1 SCr increase ≥25% and <0.5 mg/dL above baseline MACE 19.4%
Mortality 10.4%
Grade 2 SCr increase ≥0.5 mg/dL above baseline MACE 28.6%
Mortality 40.9%
CIN, contrast-induced nephropathy; MACE, major adverse cardiovascular event; SCr, serum creatinine.
Table 2 Cardiovascular adverse outcomes following CIN
Adverse event Outcome: CIN group vs no CIN group
In-hospital mortality 7.1% vs 1.1% (p<0.0000001)
McCullough et al,25 n=1826
1 year mortality 37.7% vs 19.4% (p=0.001)
Gruberg et al,27 n=439
Persistent worsening of renal function
(eGFR>25% baseline at 3/12)
18.6% vs 0.9% (p=0.0001)
Maioli et al,28 n=1490
Haemodialysis 0.7% McCullough et al25
7% Gruberg et al27
CIN, contrast-induced nephropathy; CM, contrast media; eGFR, estimated glomerular filtration rate.
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complex confounders associated with MACE, CIN
clinical trials that focus exclusively on clinically
important renal outcomes, such as persistent wor-
sening of renal function, new onset proteinuria and
progression to end-stage renal failure (ESRF), may
to some degree circumvent any spurious relation-
ship that is seen with MACE correlates.
Despite the lack of evidence supporting any
direct causality effect on MACE, the onset of CIN
following cardiac procedures remains an ominous
event which should prompt additional clinical vigi-
lance and early intervention.
PROPOSED MECHANISMS UNDERLYING CIN
Intravascular CM are concentrated tri-iodinated
benzene compounds that are radio-opaque as a
result of their associated iodine moieties. All CM
agents are cytotoxic and this may be compounded
by the ionic strength, osmolality or viscosity of
each speciﬁc agent.31 Ionic ‘hyper-osmolar’ solu-
tions were the ﬁrst to be used; however, these
agents were found to be highly nephrotoxic and
are now rarely administered.32 As such safer agents,
including non-ionic ‘low-osmolar’ (LOCM) or ‘iso-
osmolar’ (IOCM) solutions were developed. These
formulations are signiﬁcantly more viscous than
blood plasma, with viscosity inversely related to
osmolality33 (table 3). These two physicochemical
properties of CM are thought to be implicated in
the pathogenesis of CIN in addition to direct vaso-
active and cytotoxic effects.34
The kidney is particularly vulnerable to ischae-
mic injury as it is subjected to high metabolic and
osmotic stress and it is supplied by an intricate
microvascular circulation susceptible to local and
systemic hypoperfusion. This is most evident in the
outer medullary region of the kidney where oxygen
requirements are high due to active sodium resorp-
tion in the ascending loop of Henle and the partial
pressure of oxygen is low at approximately
20 mmHg.35 This relative ischaemia is related to the
delicate blood supply provided for by the descend-
ing vasa recta (DVR), which is a long and narrow
diameter vessel with high vascular resistance, and
which may be further compounded by arterioven-
ous shunting.36 Patients with CKD are at an add-
itional risk of renal ischaemia due to the increased
metabolic demands placed on a reduced nephron
bed which is often coupled with a compromised
microvascular and macrovascular circulation.37
Although understanding of the complex patho-
genesis of CIN is incomplete, the primary model
identiﬁes ischaemia in the vulnerable outer
medullary region of the kidney as being pivotal.36
Following intravascular administration of CM, a
prolonged period of renal vasoconstriction occurs
due to an imbalance of local vasoactive mediators,
such as nitrous oxide,38 adenosine, endothelin,39
prostaglandin and reactive oxygen species (ROS)40
which are released by the vascular endothelium in
direct response to CM cytotoxicity. The resulting
ischaemic tissue releases further noxious vasoactive
mediators including ROS, thus prolonging the dur-
ation of vasoconstriction.
The increased viscosity of the admixture of CM
and blood plasma within the DVR results in a
further reduction in medullary blood ﬂow41 and
the hyperosmolality of CM in plasma has been
shown to cause red cell distortion and aggregation
which may also contribute to reduced perfusion
due to capillary obstruction.42 As CM is ﬁltered
and concentrated within the tubules, the resulting
increase in viscosity causes tubular obstruction
which, coupled with ROS release, induces an acute
tubular injury.43 Thus, the combination of cytotox-
icity, vasoconstriction and viscosity present a potent
combination for the induction of medullary ischae-
mia/reperfusion injury (ﬁgure 1).
The risk of CIN is increased in elderly patients
and those with diabetes or CKD, which may be
due to the presence of endothelial dysfunction and
an exaggerated vasoconstrictive response to CM.44
Equally, patients with poor pre-renal perfusion,
such as those with congestive cardiac failure (CCF),
renovascular disease or intravascular volume deple-
tion, are also at increased risk of CIN due to the
deleterious effect of renal vasoconstriction coupled
with low preload. As observed in clinical studies,
the presence of anaemia and thus reduced oxygen
carrying capacity of blood would be expected to
worsen ischaemia in the outer medullary region of
the kidney.45
RISK FACTORS AND RISK ASSESSMENT
In order to reduce the chance of CIN occurrence it
is important to review the risk factors and indica-
tions for CM administration prior to any CM pro-
cedure. Most CIN risk factors can be assessed from
the clinical history, physical examination and
common laboratory investigations. Further risk
factors may become apparent periprocedurally.
Pre-existent CKD is probably the most important
pre-procedural risk factor for CIN. The European
Society of Urogenital Radiology Consensus
Working Panel46 in 1999 stated that CIN risk
becomes clinically signiﬁcant when baseline SCr
concentration is ≥1.3 mg/dL (≥115 mmol/L) in
men and ≥1.0 mg/dL (≥88.4 mmol/L) in women.
These ﬁgures approximate to an eGFR <60 mL/
min/1.73 m2, which deﬁnes CKD stages 3–5 and
which is now generally recognised as the threshold
for CIN risk.47 This simple biochemical assessment
is the most widely adopted screening tool;
however, it is important to recognise that SCr is an
insensitive measure of renal function and that other
risk factors are highly contributory to CIN, which
can occur in patients without pre-existent CKD.5
Table 3 Comparison of CM agents by osmolality and viscosity
Blood plasma
Iso-osmolar
eg, Visipaque
Low-osmolar
eg, Omnipaque
High-osmolar
eg, Hypaque
Osmolality 290 mosmol/L 290 mosmol/L 890 mosmol/L 2100 mosmol/L
Viscosity 3–4 mPa s 8.8 mPa s 6.8 m mPa s 4.1 mPa s
CIN risk N/A Low Low High
CIN, contrast-induced nephropathy; CM, contrast media.
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Based on clinical experience, dehydration is a
major risk factor for CIN; however, as it is largely
a clinical diagnosis and is challenging to quantify, it
has never been formally investigated in clinical
trials. Hypotension, deﬁned as a systolic blood
pressure of <80 mm Hg for more than 60 min, is a
recognised risk factor for CIN, attributable to intra-
vascular volume depletion (eg, severe dehydration,
haemorrhage or sepsis), cardiogenic shock (eg,
AMI) or excessive vasodilation (eg, anaphylaxis)
which results in renal hypoperfusion and thus
increased sensitivity to CM-induced renal ischae-
mia. The presence of CCF classiﬁed according to
New York Heart Failure Association III or IV, a
recent history of pulmonary oedema,9 AMI,6 or LV
ejection fraction of less than 45% have all been
shown to be independent risk factors.48 49 Diabetes
mellitus is also an independent CIN risk factor as
demonstrated in a number of clinical trials,9 48
especially so when coexistent with CKD.50
Advanced age, usually quantiﬁed as over 75 years,9
is also associated with CIN. Anaemia is another
important risk factor, usually deﬁned as a haemato-
crit (HCT) of less than 0.39 in males or 0.36 in
females.45 The coadministration of nephrotoxic
agents (see table 6), are thought to increase the risk
of CIN, although this is not well documented in
clinical studies.51 There is conﬂicting evidence
regarding the risk of concurrent treatment with
ACE inhibitors and angiotensin receptor blocker’s
(ARB’s), however if part of established therapy,
continuation is considered safer than the risk of
withdrawal.47
Procedural factors such as the total volume of
CM9 (>350 mL or >4 mL/kg) and previous CM
exposure within 72 h8 are directly related to the
development of CIN. A speciﬁc method for quanti-
fying the maximum safe volume of contrast has
been proposed by Laskey et al52 who demonstrated
that a ratio of the volume of contrast media to cre-
atinine clearance (V/CrCl) greater than 3.7:1 corre-
lates strongly with the risk of developing CIN
in patients with moderate CKD undergoing CA.
In addition, the presence of periprocedural
haemodynamic instability requiring the use of ino-
tropic agents or intra-arterial balloon pump9
therapy is particularly high-risk feature. A number
of these risk factors have been integrated into a
well-known post-procedure risk scoring system and
validated in a large cohort study by Mehran et al9
(table 4).
A similar scoring system has also been proposed
by Tziakas et al53 who found that pre-existing renal
disease, metformin use, history of previous PCI,
peripheral arterial disease and ≥300 mL of contrast
volume were also independent predictors of CIN.
A limitation of these scoring systems is that calcula-
tion is only possible after CM has been adminis-
tered. However, it is clinically desirable to be able
to predict the risk of CIN before the patient is
exposed to CM allowing appropriate precautionary
measures to be taken. Such a pre-procedural CIN
risk score has been proposed by Maioli et al,8 fol-
lowing validation in a prospective cohort study
(table 5).
A number of other novel CIN risk factors have
been identiﬁed, including pre-procedure glucose
levels54 55 and low-density lipoprotein choles-
terol;56 however, these have yet to be integrated
into risk scoring systems. It may be possible to use
commonly used cardiovascular risk scoring
methods to approximate CIN risk, for example, a
Global Registry of Acute Coronary Events score of
>140 in patients with AMI having normal baseline
renal function has been shown to predict risk of
CIN in a small cohort study.57 A novel ﬂuid status
assessment method using Bio-Impedance Vector
Analysis has also been demonstrated to independ-
ently predict CIN58 in a small clinical trial;
however, it has not yet been translated into a CIN
risk scoring system or guided volume repletion
strategy.
ESTABLISHED PREVENTATIVE MEASURES
In 2014, the European Society of Cardiology pub-
lished updated guidelines on CIN59 prevention
which provides a framework for the use of the fol-
lowing evidence-based strategies (ﬁgure 2 and
Figure 1 Pathophysiological
mechanism underlying CIN is shown.
CIN, contrast-induced nephropathy;
NO, nitric oxide, ROS, reactive oxygen
species. Adapted from Seeliger et al.89
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table 6). For all patients referred for CM proce-
dures, a CIN risk assessment should be performed
which includes baseline measurement of SCr and
calculation of eGFR using a suitable formula, for
example, Modiﬁcation of Diet in Renal Disease or
Chronic Kidney Disease–Epidemiology. If patients
are identiﬁed as being at risk of CIN, particularly if
eGFR is <40 mL/min, clinical indications for the
CM procedure should be reviewed and preventative
measures instigated. A single invasive approach
should ideally be adopted, with CA followed by ad
hoc PCI to reduce the risk of atheroembolic com-
plications while minimising contrast volumes to
<4 mL/kg or V/CrCl <3.7:1. However if a second
CM procedure is necessitated, it is advisable to
delay until adequate clearance of CM and recovery
from any renal injury has occurred, which may be
up to 2 weeks or as long as is clinically acceptable.
It should be acknowledged that due to the overlap
of common risk factors, patients at risk for CIN are
also at signiﬁcantly higher risk of cardiovascular
events and therefore should not be excluded or
unnecessarily delayed from receiving prognostic
CM procedures unless the risks are considered to
be excessive.
Patients should be advised to stop all non-essential
nephrotoxic medications (table 7) for 24 h prior to
and for 48 h following the CM procedure pending
SCr measurement. It is also recommended that
patients receiving intra-arterial CM with an eGFR of
<60 mL/min/1.73 m2, or those receiving intravenous
CM with an eGFR of <45 mL/min/1.73 m2, discon-
tinue metformin for 48 h prior to CM exposure and
restart once a 48 h SCr measurement excludes CIN.
This is to mitigate the risk of lactic acidosis due to
reduced renal clearance of metformin that may occur
following a potential CIN episode, rather than met-
formin nephrotoxicity per se.
Recent studies have investigated whether IOCM
formulations, which are thought to induce less
osmotic stress despite generally having higher vis-
cosity, are preferable over LOCM. A number of
meta-analyses have been performed, some of which
suggest the superiority of IOCM; however, others
have shown no beneﬁt.60 61 The current guidelines
recommend the use of either IOCM or LOCM,
although a preference for IOCM is reasonable,
with the more important proviso that the minimum
amount of CM required for diagnostic accuracy is
used. During CA or PCI, the use of biplane
imaging by experienced operators may reduce the
amount of contrast required as simultaneous
orthogonal views can be acquired following each
CM injection.62
The most effective prophylactic intervention is
provision of adequate hydration prior to CM
exposure. Supplementing intravascular volume
ensures renal blood ﬂow is maintained and acts to
dilute CM in both blood plasma and tubular ﬁl-
trate. In lower risk ambulant patients, the oral
route may be appropriate if adequate ﬂuid intake is
assured. However, in moderate/higher risk or in
hospitalised patients intravenous hydration with a
crystalloid ﬂuid is preferred over oral hydration as
it guarantees delivery of appropriate ﬂuid volumes
and has been demonstrated as superior in clinical
trials.63 The choice of which crystalloid to use is,
however, less clear; when compared with isotonic
(normal) saline (0.9%), intravenous sodium bicar-
bonate (1.26%) may have additional ROS scaven-
ging properties mediated through urine
alkalinisation64 and lacks chloride ions that are
thought to exacerbate renal vasoconstriction.65 Two
recent meta-analyses have demonstrated a modest
reduction in CIN when using intravenous sodium
bicarbonate 1.26% as compared with isotonic
saline,66 67 although no signiﬁcant mortality beneﬁt
has been demonstrated. In view of the current lack
of evidence supporting the use of sodium bicarbon-
ate 1.26% and with some studies offering conﬂict-
ing evidence,68 the current ESC guidelines
recommend pre-hydration with sodium chloride
0.9% at 1–1.5 mL/kg/h for 12 h pre-procedure and
up to 24 h post procedure. For elective day case
patients and for those with CCF in whom large
volumes of intravenous ﬂuid may provoke pulmon-
ary oedema,69 it is also reasonable to use an
Table 5 A pre-procedural risk score for CIN (adapted from Maioli et al8)
Pre-procedural risk factor Score
Prior CM exposure within 72 h 3
Left ventricular ejection fraction <45% 2
Pre-procedure SCr >baseline SCr 2
Baseline SCr >1.5 mg/dL 2
Diabetes mellitus 2
Creatinine clearance (eGFR) <44 mL/min 2
Age >73 years 1
Score 0–3 4–6 7–8 >9
CIN risk Low 1.1% Moderate 7.5% High 22.3% Very high 52.1%
CIN, contrast-induced nephropathy; CM, contrast media; eGFR, estimated glomerular filtration rate; SCr,
serum creatinine.
Table 4 The Mehran risk score for the prediction of CIN9
Mehran score periprocedural CIN risk factor Score
Hypotension (SBP <80 mm Hg or >1 h of inotropic support) 5
Intra-arterial balloon pump therapy 5
Chronic heart failure, (NYHA III/IV or recent pulmonary oedema) 5
Age >75 years 4
Diabetes mellitus 3
Anaemia (male: HCT<0.39, female: HCT<0.36) 3
Estimated glomerular filtration rate <20 mL/min 6
Estimated glomerular filtration rate 20–40 mL/min 4
Estimated glomerular filtration rate 40–60 mL/min 2
Contrast media volume 1 per cc
Score <5 6–10 11–16 >16
CIN risk Low 7.5% Moderate 14% High 26.1% Very high 57.3%
Dialysis risk 0.04% 0.12% 1.09% 12.6%
CIN, contrast-induced nephropathy; HCT, haematocrit; NYHA, New York Heart Failure Association;
SBP, systolic blood pressure.
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Table 6 European Society of Cardiology CIN prevention guidelines, 2014
Recommendation Detail ClassLevel
Intravenous hydration with isotonic saline is recommended I A
Use of either LOCM or IOCM is recommended <350 mL or <4 mL/kg or V/CrCl <3.7:1 I A
IOCM use should be considered over LOCM IIa A
Short term, high-dose statin therapy should be considered Rosuvastatin 20/40 mg or atorvastatin 80 mg or simvastatin 80 mg IIa A
Volume of CM should be minimised IIa B
A CIN risk assessment should be performed IIa C
In patients at very high CIN risk or when prophylactic hydration is
impossible, furosemide with matched hydration may be considered over
standard hydration
250 mL 0.9% saline intravenously over 30 min (or ≤150 mL in LV dysfunction)
with 0.25–0.5 mg/kg of furosemide intravenous bolus. Adjust intravenous fluid
rate to match urine output until >300 mL/h then perform CM procedure.
Continue matched fluid replacement for 4 h post procedure
IIb A
In severe CKD, prophylactic haemofiltration prior to complex PCI may be
considered
Fluid replacement rate 1 L/h without negative loss, 0.9% sodium chloride
intravenous hydration for 24 h post procedure
IIb B
N-acetyl-cysteine instead of intravenous hydration is not recommended III A
Infusion of 8.4% sodium bicarbonate instead of 0.9% sodium chloride is
not recommended
III A
In severe CKD prophylactic renal replacement therapy is not routinely
recommended
III B
CIN, contrast-induced nephropathy; CKD, chronic kidney disease; CM, contrast medium; IOCM, iso-osmolar contrast medium; LOCM, low-osmolar contrast medium; LV, left ventricular;
PCI, percutaneous coronary intervention; V/CrCl, volume of contrast media to creatinine clearance.
Adapted from Windecker et al.59
Figure 2 Algorithm for the
prevention of CIN is shown. AKI, acute
kidney injury; BP, blood pressure; CHF,
chronic heart failure; CIN,
contrast-induced nephropathy; eGFR,
estimated glomerular ﬁltration rate;
IOCM, iso-osmolar contrast medium;
LOCM, low-osmolar contrast medium;
MI, myocardial infarction; NaCl,
sodium chloride; NaHCO3
−, sodium
bicarbonate; Scr, serum creatinine;
V/CrCl, volume of contrast media to
creatinine clearance.
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alternative protocol delivering a shorter duration
and volume of sodium chloride 0.9% (table 8).
All patients determined as being at risk of CIN
should have SCr levels measured between 48 and
72 h following CM exposure. If CIN is diagnosed,
then it should be managed using recommended AKI
guidelines, such as the recent European Best Practice
position statement on AKI.70 This includes follow-up
SCr measurements, withdrawal of nephrotoxic medi-
cations and unnecessary loop diuretics, electrolyte
and hydration optimisation, nutritional advice and, if
severe AKI occurs, early hospitalisation with referral
to a specialist nephrologist.
NOVEL PREVENTATIVE MEASURES
A number of prophylactic pharmacological agents
have been investigated; however, at present the evi-
dence for beneﬁt in CIN prevention is limited.
Originally one of the most promising agents,
N-acetyl-cysteine (NAC), is inexpensive, well toler-
ated and has both antioxidant and vasodilatory
properties. Several large RCTs have shown oral
NAC at dose of 600 mg twice a day for 24 h pre-
procedure and post procedure reduces the inci-
dence of CIN.71 72 However meta-analyses73 74
have failed to reach consensus, most likely due to
clinical heterogeneity, variable reporting and publi-
cation bias in the included studies.75 As such the
ESC guidelines recommend that NAC is not to be
used alone, although it may be used in addition to
standard intravenous hydration regimes.70 More
recently high-dose statin therapy (eg, rosuvastatin
40/20 mg, atorvastatin 80 mg or simvastatin 80 mg)
has shown efﬁcacy in preventing CIN in
statin-naïve patients in several clinical studies76 77
and as such is regarded as reasonable preventative
therapy in the current ESC guidelines. Other
pharmaceutical agents with antioxidant (eg, ascor-
bic acid) and vasodilatory properties have also been
investigated and although some have shown
promise, further evaluation is required (table 9).
There has also been considerable interest in
novel interventional therapies that may offer add-
itional protection when combined with conven-
tional therapy. These can be characterised into
three categories: direct renal protection, hydration
optimisation and CM delivery and extraction tech-
nologies. The prototypical renal protection
approach is exempliﬁed by remote ischaemic pre-
conditioning, which has been shown in many
models to be cytoprotective against ischaemia/
reperfusion injury, believed to be characteristic of
CIN.78 Several small RCTs have shown promise
using cycles of brief, non-injurious remote tissue
ischaemia to trigger renal protection. Both blood
pressure cuff inﬂation on the upper arm prior to
CM exposure (preconditioning)79 and catheter
balloon inﬂation in the target coronary artery fol-
lowing PCI (post-conditioning)80 81 have demon-
strated a 60%–70% reduction in the incidence of
CIN. Although encouraging, larger Phase II/III
studies are required to conﬁrm efﬁcacy of this safe
and cost–effective intervention.
Two hydration optimisation strategies have been
trialled in CIN: LV end diastolic pressure (LVEDP)
guided volume expansion and high urine output
matched ﬂuid replacement (RENALGUARD). The
optimum rate and volume of intravenous ﬂuid
delivery represents a signiﬁcant challenge: under-
hydration increases CIN risk, whereas overhydra-
tion may precipitate acute pulmonary oedema in
vulnerable patients with severe CKD and CCF. The
recent POSEIDON RCT82 demonstrated that
LVEDP-guided volume expansion in at-risk patients
was safe and signiﬁcantly reduced the incidence of
CIN from 16.3% (28/172) in controls to 6.7% (12/
178) in the ﬂuid-guided group. An alternative ﬂuid
management system is delivered by the
RENALGUARD system, which maintains a high
urine output (>300 mL/h) using balanced intraven-
ous isotonic saline (0.9%) delivery and intravenous
furosemide infusion (0.25 mg/kg). The REMEDIAL
II study83 demonstrated superiority of the
RENALGUARD system plus oral NAC in prevent-
ing CIN (11%, 16/146) against a control group
receiving sodium bicarbonate (1.26%) regimen plus
oral NAC (20.5%, 30/146; OR 0.47; 95% CI 0.24
to 0.92). As such these novel therapies hold
promise for higher risk patients especially those
who are physiologically unable to tolerate large
intravenous ﬂuid volumes.
In order to minimise CM load, novel automated
contrast injection devices have been developed
which decrease the volume of CM used and which
have been shown to reduce the incidence of CIN.84
It has been proposed that rapid removal of CM
from the blood pool may have beneﬁt in preventing
CIN; although prophylactic HD has not been
shown attenuate the incidence of CIN,85 some
beneﬁt has been observed with both pre-procedural
and post-procedural86 haemoﬁltration (HF) and
simultaneous HF,87 which may be partially
explained through optimisation of periprocedural
intravascular volumes. However, HF is a
resource-intensive therapy that should be reserved
Table 7 Nephrotoxic medications requiring withdrawal 24 h pre-procedure
Drug class Examples
Non-steroidal anti-inflammatory Naproxen, Ibuprofen, Diclofenac, Celecoxib90
Antibiotics Aminoglycosides: (Gentamycin, Tobramycin, Amikacin)91
Antifungals Amphotericin B92
Antivirals Acyclovir, Tenofovir, Foscarnet93
Immunomodulatory Ciclosporin A94
Antineoplastic Cisplatin, Ifosfamide, Mitomycin95
Table 8 Intravenous pre-hydration regimes, Updated ESUR guidelines 201147
Intravenous fluid Pre-hydration Post-hydration
Isotonic saline (0.9%) 12 h, 1–1.5 mL/kg/h 12–24 h, 1–1.5 mL/kg/h
Isotonic saline (0.9%) or sodium
bicarbonate (1.26%)
1 h at 3 mL/kg/h 6 h at 1 mL/kg/h
ESUR, European Society of Urogenital Radiology.
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for very-high-risk patients, such as for those with
pre-dialysis ESRF88 or those with severe CKD
undergoing complex PCI. Direct extraction of CM
in coronary venous blood, captured using a coron-
ary sinus catheter, is an interesting experimental
intervention89 which has yet to be proven in clin-
ical trials.
SUMMARY AND CONCLUSION
CIN represents a signiﬁcant clinical and health eco-
nomic problem that may be under-recognised
through limitations in the currently available bio-
markers. Although often a transient injury, CIN
may progress to signiﬁcant persistent renal impair-
ment, ESRF and adverse cardiovascular outcomes.
There are a number of recognised risk factors,
although the prediction of CIN, particularly prior
to contrast administration, remains challenging.
Current interventions are largely centred on the
avoidance of dehydration, the withdrawal of
nephrotoxic agents and minimisation of contrast
load, which has limited efﬁcacy in preventing CIN
in vulnerable patients. The unmet clinical need in
CIN therefore resides in accurate prediction, effect-
ive intervention and rapid detection to prevent
adverse cardiorenal outcomes. Each of these areas,
particularly predictive risk scoring systems, innova-
tive pharmacological and mechanical interventions
and novel biomarkers are currently the subject of
intensive research and development that may lead
to the future development effective strategies to
mitigate the risk of CIN.
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